Fosun Pharma to repurchase shares, adjust subsidiary equity

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (HKEX: 2196) announced it will repurchase and cancel 897,140 restricted A shares under its 2022 incentive scheme for RMB19,100,110.60. This decision follows the resignation of certain participants and the non-achievement of performance targets for 2024. The repurchase reduces the company's total issued share capital from 2,671,326,465 to 2,670,429,325 shares.